Literature DB >> 11899421

Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

S M Anderton1.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11899421      PMCID： PMC1783326          DOI： 10.1046/j.1365-2567.2001.01324.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  101 in total

1.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes.

Authors:  F Crawford; H Kozono; J White; P Marrack; J Kappler
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

Review 2.  A very high level of crossreactivity is an essential feature of the T-cell receptor.

Authors:  D Mason
Journal:  Immunol Today       Date:  1998-09

3.  A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11.

Authors:  C I Pearson; A M Gautam; I C Rulifson; R S Liblau; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

4.  Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis.

Authors:  A Corthay; J Bäcklund; J Broddefalk; E Michaëlsson; T J Goldschmidt; J Kihlberg; R Holmdahl
Journal:  Eur J Immunol       Date:  1998-08       Impact factor: 5.532

5.  Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.

Authors:  R Aharoni; D Teitelbaum; M Sela; R Arnon
Journal:  J Neuroimmunol       Date:  1998-11-02       Impact factor: 3.478

6.  Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

Authors:  M Fridkis-Hareli; E F Rosloniec; L Fugger; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

7.  Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide.

Authors:  E A Leadbetter; C R Bourque; B Devaux; C D Olson; G H Sunshine; S Hirani; B P Wallner; D E Smilek; M P Happ
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

8.  Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes.

Authors:  A Geluk; K E van Meijgaarden; B O Roep; T H Ottenhoff
Journal:  J Autoimmun       Date:  1998-08       Impact factor: 7.094

9.  Fine specificity of the myelin-reactive T cell repertoire: implications for TCR antagonism in autoimmunity.

Authors:  S M Anderton; S P Manickasingham; C Burkhart; T A Luckcuck; S J Holland; A G Lamont; D C Wraith
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

10.  IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice.

Authors:  E Bettelli; M P Das; E D Howard; H L Weiner; R A Sobel; V K Kuchroo
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422
View more
  13 in total

Review 1.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 2.  Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.

Authors:  Joseph J Sabatino; Kristen M Rosenthal; Brian D Evavold
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-11       Impact factor: 4.147

3.  Construction of the recombinant vaccine based on T-cell epitope encoding Der p1 and evaluation on its specific immunotherapy efficacy.

Authors:  Jinhong Zhao; Chaopin Li; Beibei Zhao; Pengfei Xu; Haifeng Xu; Lianping He
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 4.  Natural and induced regulatory T cells: targets for immunotherapy of autoimmune disease and allergy.

Authors:  Kirsty S Nicolson; David C Wraith
Journal:  Inflamm Allergy Drug Targets       Date:  2006-09

Review 5.  Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.

Authors:  Chunsong Yu; Jingchao Xi; Meng Li; Myunggi An; Haipeng Liu
Journal:  Bioconjug Chem       Date:  2017-12-06       Impact factor: 4.774

6.  Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus.

Authors:  Sayed Mahdi Marashi; Mohammad Raeiszadeh; Sarita Workman; Afsar Rahbar; Cecilia Soderberg-Naucler; Paul Klenerman; Ronnie Chee; A David Webster; Richard S B Milne; Vincent C Emery
Journal:  J Allergy Clin Immunol       Date:  2011-05-04       Impact factor: 10.793

7.  Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis.

Authors:  Melanie D Leech; Chen-Yen Chung; Abigail Culshaw; Stephen M Anderton
Journal:  Eur J Immunol       Date:  2007-12       Impact factor: 5.532

8.  Combination peptide immunotherapy based on T-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation.

Authors:  Karen J Mackenzie; Paul M Fitch; Melanie D Leech; Anne Ilchmann; Claire Wilson; Amanda J McFarlane; Sarah E M Howie; Stephen M Anderton; Jürgen Schwarze
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

9.  A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificities.

Authors:  Maurizio Provenzano; Giovanni Sais; Laura Bracci; Adrian Egli; Maurizio Anselmi; Carsten T Viehl; Stefan Schaub; Hans H Hirsch; David F Stroncek; Francesco M Marincola; Giulio C Spagnoli
Journal:  J Cell Mol Med       Date:  2009-08       Impact factor: 5.295

10.  Effector and central memory T helper 2 cells respond differently to peptide immunotherapy.

Authors:  Karen J Mackenzie; Dominika J Nowakowska; Melanie D Leech; Amanda J McFarlane; Claire Wilson; Paul M Fitch; Richard A O'Connor; Sarah E M Howie; Jürgen Schwarze; Stephen M Anderton
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.